English Global
Panacea Biotec, one of India’s leading biotechnology companies, has received long-term supply awards worth US$ 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT® (DTwP-HepB-Hib).
UNICEF award is worth US$ 98.755 million (~INR 813 Crore) for supply of ~99.70 million doses during calendar years 2023-2027 and PAHO award is worth US$ 28.55 million (~INR 235 Crore) for supply ~24.83 million doses during calendar years 2023-2025.
Paediatric vaccination plays an important role to achieve Sustainable Development Goals (SDGs) set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births. Pentavalent vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b – becoming the foundation of paediatric immunization programs across the world.
Easyfive-TT is the world’s first fully liquid wP-based Pentavalent vaccine that as launched in India in 2005. After receiving WHO prequalification in 2008, more than 150 million doses have been supplied to over 75 countries globally. EasyFive-TT is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders. As per Human Vaccines and Immunotherapeutics[1], the fully-liquid Pentavalent vaccine has been hailed as a “breakthrough in India’s Universal Immunisation Program” with having averted more than 7 million cases, averted ~31,000 deaths, and total benefits exceeding US $ 1 billion in DALY savings in India.
Dr. Rajesh Jain, Managing Director, Panacea Biotec said, “We are delighted to receive the notification of UNICEF and PAHO awards for Pentavalent vaccine at this important juncture in Panacea Biotec’s journey. As we celebrate India’s 75 years of independence ‘Azadi ka Amrit Mahotsav’ , this showcases the growing role India plays to support global health. We are excited to continue to save lives by supporting U.N. Agencies and partners for global immunization programs and to bring to market additional vaccines in coming years to meet programmatic needs of UNICEF and PAHO.”
***
About Panacea Biotec
Panacea Biotec is a leading pharmaceutical and biotechnology company with established research, manufacturing and marketing capabilities. Panacea Biotec has pioneered in the development of innovative fully-liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. We have also launched world’s first fully liquid wP-IPV based hexavalent vaccine EasySix™ (DTwP-HepB-Hib-IPV) in India in March 2017.
The other key vaccines in portfolio are EasyFour®-TT (DTwP-Hib), IPV based tetravalent vaccine – EasyFour®-Pol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Panacea Biotec’s new vaccines in pipeline are Pneumococcal Conjugate Vaccine - NucoVac-11® and Recombinant Tetravalent Dengue Candidate Vaccine - DengiALL® and Td (tetanus and diphtheria – reduced).
Panacea Biotec remains focused on merging cutting-edge science and technology with an unwavering commitment towards unmet medical needs while ensuring affordability. It has research collaborations with leading national and international research organizations and corporations. Panacea Biotec has around 2,000 employees.
For more information, visit: www.panaceabiotec.com Follow our news page for the latest updates. Follow us via @PanaceaBiotec and LinkedIn.
****
For more information:
For Investors
Mr. Devender Gupta
Chief Financial Officer and Head Information Technology
Tel: + 91-11-41679000 Ext. 1225, 41578011 (Direct)
Email: devendergupta@panaceabiotec.com
For Media
Mr. P. D. Karan
Vice President - Corporate Communication & Business Development
Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)
Mobile: + 91 9312693040, + 91 9810500539
Email: pdkaran@panaceabiotec.com
[1] Bairwa M, Pilania M, Rajput M, Khanna P, Kumar N, Nagar M, Chawla S. Pentavalent vaccine: a major breakthrough in India's Universal Immunization Program. Hum Vaccin Immunother. 2012 Sep;8(9):1314-6. doi: 10.4161/hv.20651. Epub 2012 Aug 16. PMID: 22894968; PMCID: PMC3579914.